SA EMS ROAD EXPERIENCE • HPCSA STATUTORY DRUG MONOGRAPH
SUXAMETHONIUM CHLORIDE (SUCCINYLCHOLINE)
Suxamethonium Chloride / Succinylcholine (Brand Names: Scoline, Anectine, Quelicin)
HPCSA CDST 2024 (Version 1.3 Framework)
Official Statutory Clinical Reference
Depolarizing Neuromuscular Blocker • Acetylcholine Receptor Agonist • RSI Alternative AgentHPCSA CDST 2024 (v1.3 Framework)
•
SUXAMETHONIUM CHLORIDE (SUCCINYLCHOLINE)
Suxamethonium Chloride / Succinylcholine (Brand Names: Scoline, Anectine, Quelicin)
Clinical Summary: An ultra-rapid, short-acting depolarizing neuromuscular blocker composed of two linked acetylcholine molecules that produces immediate motor endplate depolarization and profound flaccidity within 45 seconds for emergency RSI.
Authorized HPCSA Emergency Care Scope of Practice (Annexure A 2022)Statutory Board Mandate
ECP ONLY (~)
SUXAMETHONIUM CHLORIDE (SUCCINYLCHOLINE) Audio BriefingCLINICAL PROFESSOR
No Audio Published Yet
00:00Full Monograph
1. Mechanism of Action
How this drug operates physiologically in the human body
2. Statutory Clinical Indications
1 UsesStrictly per HPCSA CDST v1.3, Annexure A & CPG
3. Adverse Effects & Pathophysiology
Why the body reacts and why it occurs in specific indications
4. Contraindications & Lethal Risks
Biological consequences & why it threatens life
5. Statutory Resources & Quotes
Verbatim regulatory excerpts with deep external links
SA EMS FIELD PROTOCOLS • EDUCATIONAL REVIEW & STATUTORY CITATIONS
An independent educational review and study companion based on the official HPCSA CDST 2024 (Version 1.3 Framework), CPG 2018, and Annexure A (2022) sourced directly from the official HPCSA publication portal. Not for live on-scene patient management.
Author: Jacoline (Jax) Geldenhuys, BEMC • HPCSA Registered Emergency Care Practitioner (ECP)